Croatia
Key Insights
- 1
No psychedelic is approved in Croatia; legal patient access is effectively limited to esketamine within standard psychiatric practice under EU authorisation.
- 2
Blossom logs 1 Croatian trial, and it is active; the only compound tracked is esketamine, with no other psychedelic compounds studied.
- 3
Croatia’s standout marker is not a domestic psychedelic programme but its inclusion in EU esketamine authorisation pathways via Spravato’s 2019 European Commission approval.
- 4
Momentum is thin but real: EUDA says (es)ketamine is the most commonly trialled psychedelic class, and Croatia’s lone active study keeps the country on that map.
Reimbursed Care Access
Croatia classifies most classic psychedelic compounds as controlled substances under its Law on Combating Drug Abuse; possession of small amounts was decriminalized as a misdemeanour in 2013 but medical/therapeutic access is limited. The only psychedelic-derived medicine with an EU marketing authorisation (esketamine/Spravato) is authorised at the EU level and may be supplied in Croatia under usual pharmaceutical channels, while ketamine is available as an approved anaesthetic and is used off‑label in some private settings for psychiatric indications. Other compounds (psilocybin, MDMA, DMT, 5‑MeO‑DMT, ibogaine, ayahuasca, mescaline, 2C‑X) have no authorised medical use in routine care and are subject to national drug‑control measures except within approved research. [https://narodne-novine.nn.hr/clanci/sluzbeni/full/2001_12_107_1756.html|Narodne Novine — Law on Combating Drug Abuse] [https://www.ema.europa.eu/en/medicines/human/EPAR/spravato|EMA — Spravato EPAR]
Quick Indicators
Research Events
Clinical Trials
Active and completed clinical trials investigating psychedelic-assisted therapies in Croatia.